The document summarizes HIV/AIDS surveillance data in Europe for 2017. Some key findings are:
- 25,353 new HIV diagnoses were reported in 30 EU/EEA countries in 2017.
- Sex between men accounted for 38% of new diagnoses, while heterosexual transmission accounted for 33%.
- Nearly half (49%) of individuals were diagnosed late, with a CD4 count below 350 cells/mm3.
- Migrants accounted for 41% of new diagnoses, many originating from sub-Saharan Africa and Latin America.
Providing an overview on data, trends and summary of findings on the hepatitis B and C surveillance data from EU/EEA countries for the year 2017:
Find ECDC's Annual Epidemiological reports online: http://bit.ly/ECDCAER
Summary slides on the epidemiological situation in the EU/EEA.
2018 surveillance data.
Report and ppt slides available from: http://bit.ly/HIVAIDSsurv18
Presentation at European Harm Reduction Conference
Bucharest, 21 November 2018
Author Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC)
Hepatitis E is one of the most common causes of acute hepatitis in the EU/EEA but currently not notifiable at EU level.
This presentation summarises ECDC's work on the topic and survey results on hepatitis E on 2005 to 2015 data.
Any questions? Contact press@ecdc.europa.eu
ECDC symposium "Responding to two of the main STI threats of our time: syphilis and antimicrobial resistant Neisseria gonorrhoeae"
Presentation by: Otilia Mårdh
Presented at: IUSTI 2019, Tallinn
This presentation summarises the main data from the ECDC Annual epidemiological reports 2017 on chlamydia, gonorrhoea, lymphogranuloma venereum, (congenital) syphilis
Providing an overview on data, trends and summary of findings on the hepatitis B and C surveillance data from EU/EEA countries for the year 2017:
Find ECDC's Annual Epidemiological reports online: http://bit.ly/ECDCAER
Summary slides on the epidemiological situation in the EU/EEA.
2018 surveillance data.
Report and ppt slides available from: http://bit.ly/HIVAIDSsurv18
Presentation at European Harm Reduction Conference
Bucharest, 21 November 2018
Author Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC)
Hepatitis E is one of the most common causes of acute hepatitis in the EU/EEA but currently not notifiable at EU level.
This presentation summarises ECDC's work on the topic and survey results on hepatitis E on 2005 to 2015 data.
Any questions? Contact press@ecdc.europa.eu
ECDC symposium "Responding to two of the main STI threats of our time: syphilis and antimicrobial resistant Neisseria gonorrhoeae"
Presentation by: Otilia Mårdh
Presented at: IUSTI 2019, Tallinn
This presentation summarises the main data from the ECDC Annual epidemiological reports 2017 on chlamydia, gonorrhoea, lymphogranuloma venereum, (congenital) syphilis
Presentation from the opening session of the 17th European AIDS Conference (EACS) 2019, Basel, Switzerland.
Presenter: Anastasia Pharris, European Centre for Disease Prevention and Control.
Presentation during the 17th European AIDS Conference (EACS) 2019 looking at the status of HIV pre-exposure prophylaxis PrEP in Europe..
Presenter: Teymur Noori, European Centre for Disease Prevention and Control (ECDC)
Data and trends from the ECDC Annual Epidemiological reports for 2016 on:
Chlamydia (http://bit.ly/AERch16)
Lymphogranuloma venereum (http://bit.ly/AERLGV16)
Gonorrhoea (http://bit.ly/AERsy16)
Syphilis (http://bit.ly/AERsy16)
Congenital syphilis (http://bit.ly/AERcs16)
See also: https://ecdc.europa.eu/en/annual-epidemiological-reports
ECDC poster at the 16th European AIDS Conference, 2017, Milan.
Authors: Lara Tavoschi, Joana Gomes-Dias, Anastasia Pharris, the EU/EEA HIV Surveillance Network
Teymur Noori, ECDC
22nd International AIDS Conference, Amsterdam 2018
2018 European African HIV/AIDS & Hepatitis C Community Summit. "Our Voices Matter for a lasting solution!!"
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2015, almost 30 000 people were diagnosed in European Union and European Economic Area Member States; a rate of 6.3 cases in every 100 000 people (when adjusted for reporting delay).
This report, prepared jointly with the WHO Regional Office for Europe, presents data on HIV and AIDS for the whole European Region, including the EU and EEA countries. Analyses are provided for the EU and EEA region.
What is the current situation of HIV in Europe and Central Asia?
How can we more effectively prevent new infections?
Presentation by Anastasia Pharris,
European Centre for Disease Prevention and Control (ECDC)
at Glasgow HIV Drug Therapy Conference
28 October 2018
In 2014, over 57 000 new cases of hepatitis B and C were reported. 22 442 cases of hepatitis B virus infection were reported in 30 EU/EEA Member States and 35 321 cases of hepatitis C were reported from 28 EU/EEA Member States.
Presentation by ECDC HIV expert Anastasia Pharris on epidemiological challenges for the HIV response in Europe.
Presented at: 16th European AIDS Conference, 26 October 2017, Milan.
Surveillance data from 2013 show high numbers of newly diagnosed hepatitis B and C cases notified across Europe. Chronic cases dominate across both diseases with a marked variation between countries: in 2013, 19 930 cases of hepatitis B virus infection were reported in 28 EU/EEA Member States, a crude rate of 4.4 per 100 000 population. 26 EU/ EEA Member States recorded 32 512 cases of hepatitis C resulting in a crude rate of 9.9 per 100 000 population.
Summary of surveillance data for hepatitis B and hepatitis C across the European Union and European Economic area for 2016.
See also:
ECDC's Annual Epidemiological Report hepatitis B: http://bit.ly/AER16HBV
ECDC's Annual Epidemiological Report hepatitis C: http://bit.ly/AER16HCV
Data and trends on hepatitis B and C for the countries of the European Union and European Economic Area.
2015 data.
See also ECDC's Annual Epidemiological Report: https://ecdc.europa.eu/en/annual-epidemiological-reports
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2014, almost 30 000 people were diagnosed in European Union and European Economic Area Member States. This slide set includes maps, graphs and tables from the 2014 HIV/AIDS surveillance report, published jointly by ECDC and WHO Europe.
Presentation on epi data during the conference "New challenges and unmet needs of children and adolescents living and ageing with HIV/AIDS", 19-22 January 2017, Bucharest, Romania
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation: ECDC Acting Director Dr Andrea Ammon.
a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
ECDC presentation at the 15th Conference of the International Society of Travel Medicine, 15 May 2017.
Presenter: Teymur Noori
Questions?
Contact info@ecdc.europa.eu
Presentation from the opening session of the 17th European AIDS Conference (EACS) 2019, Basel, Switzerland.
Presenter: Anastasia Pharris, European Centre for Disease Prevention and Control.
Presentation during the 17th European AIDS Conference (EACS) 2019 looking at the status of HIV pre-exposure prophylaxis PrEP in Europe..
Presenter: Teymur Noori, European Centre for Disease Prevention and Control (ECDC)
Data and trends from the ECDC Annual Epidemiological reports for 2016 on:
Chlamydia (http://bit.ly/AERch16)
Lymphogranuloma venereum (http://bit.ly/AERLGV16)
Gonorrhoea (http://bit.ly/AERsy16)
Syphilis (http://bit.ly/AERsy16)
Congenital syphilis (http://bit.ly/AERcs16)
See also: https://ecdc.europa.eu/en/annual-epidemiological-reports
ECDC poster at the 16th European AIDS Conference, 2017, Milan.
Authors: Lara Tavoschi, Joana Gomes-Dias, Anastasia Pharris, the EU/EEA HIV Surveillance Network
Teymur Noori, ECDC
22nd International AIDS Conference, Amsterdam 2018
2018 European African HIV/AIDS & Hepatitis C Community Summit. "Our Voices Matter for a lasting solution!!"
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2015, almost 30 000 people were diagnosed in European Union and European Economic Area Member States; a rate of 6.3 cases in every 100 000 people (when adjusted for reporting delay).
This report, prepared jointly with the WHO Regional Office for Europe, presents data on HIV and AIDS for the whole European Region, including the EU and EEA countries. Analyses are provided for the EU and EEA region.
What is the current situation of HIV in Europe and Central Asia?
How can we more effectively prevent new infections?
Presentation by Anastasia Pharris,
European Centre for Disease Prevention and Control (ECDC)
at Glasgow HIV Drug Therapy Conference
28 October 2018
In 2014, over 57 000 new cases of hepatitis B and C were reported. 22 442 cases of hepatitis B virus infection were reported in 30 EU/EEA Member States and 35 321 cases of hepatitis C were reported from 28 EU/EEA Member States.
Presentation by ECDC HIV expert Anastasia Pharris on epidemiological challenges for the HIV response in Europe.
Presented at: 16th European AIDS Conference, 26 October 2017, Milan.
Surveillance data from 2013 show high numbers of newly diagnosed hepatitis B and C cases notified across Europe. Chronic cases dominate across both diseases with a marked variation between countries: in 2013, 19 930 cases of hepatitis B virus infection were reported in 28 EU/EEA Member States, a crude rate of 4.4 per 100 000 population. 26 EU/ EEA Member States recorded 32 512 cases of hepatitis C resulting in a crude rate of 9.9 per 100 000 population.
Summary of surveillance data for hepatitis B and hepatitis C across the European Union and European Economic area for 2016.
See also:
ECDC's Annual Epidemiological Report hepatitis B: http://bit.ly/AER16HBV
ECDC's Annual Epidemiological Report hepatitis C: http://bit.ly/AER16HCV
Data and trends on hepatitis B and C for the countries of the European Union and European Economic Area.
2015 data.
See also ECDC's Annual Epidemiological Report: https://ecdc.europa.eu/en/annual-epidemiological-reports
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2014, almost 30 000 people were diagnosed in European Union and European Economic Area Member States. This slide set includes maps, graphs and tables from the 2014 HIV/AIDS surveillance report, published jointly by ECDC and WHO Europe.
Presentation on epi data during the conference "New challenges and unmet needs of children and adolescents living and ageing with HIV/AIDS", 19-22 January 2017, Bucharest, Romania
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation: ECDC Acting Director Dr Andrea Ammon.
a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
ECDC presentation at the 15th Conference of the International Society of Travel Medicine, 15 May 2017.
Presenter: Teymur Noori
Questions?
Contact info@ecdc.europa.eu
During the first 2 months of 2017 we have seen 1524 cases of measles reported from 14 EU/EEA countries. Measles does not only affect children but also older age groups. In 2014 over half of the cases were in adults over 20 years old, in 2015 and 2016 this age group accounted for approximately one third of all cases. Closing immunisation gaps in adolescents and adults who have not received vaccination in the past as well as strengthening routine childhood immunisation programmes will be vital to prevent future outbreaks and reach the elimination goal.
Poster presentation at the AIDS 2018 conference in Amsterdam.
By: Marieke J. van der Werf and Csaba Ködmön, European Centre for Disease Prevention and Control, ECDC.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Masoud Dara, WHO Regional Office for Europe
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
An overview on how European countries have been responding to the HIV epidemic since 2004 based on the commitments as outlined in the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia.
Presentation by: Erika Duffell, European Centre for Disease Prevention and Control, Stockholm, Sweden
Presentad at: International Liver Congress, April 2018
Poster presentation at the AIDS 2018 conference in Amsterdam.
By: Adam Bourne1, Beatrice Alba1, Alex Garner2, Gianfranco Spiteri3, Anastasia Pharris3, Teymur Noori3
1. Australian Research Centre in Sex, Health & Society, La Trobe University, Melbourne, Australia; 2. Hornet Gay Social Network, California, USA; 3. European Centre for Disease Prevention and Control, ECDC, Sweden
Presentation by Daniel Simões, HIV in Europe, Portugal , at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Presentation by Jens Lundgren, Rigshospitalet, University of Copenhagen - European AIDS Clinical Society, Denmark, at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Presentation by Chloe Orkin, Royal London Hospital - BHIVA, United Kingdom, at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Presentation by Teymur Noori, ECDC, at AIDS 2018 conference during teh joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
More from European Centre for Disease Prevention and Control (7)
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
3. 3Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
New HIV diagnoses in the EU/EEA
2017
Reporting countries/number of countries* 30/31
Number of HIV diagnoses 25 353
Rate per 100 000 population (adjusted for reporting delay) 6.2
Male-to-female ratio 3.1
Percentage of new diagnoses CD4<350 cells/mm3
49%
Transmission mode (%)
Sex between men 38
Heterosexual transmission (men) 17
Heterosexual transmission (women) 16
Injecting drug use 4
Vertical transmission <1
Unknown 24
* Due to technical issues no 2017 data were received from Germany
4. 4
Non-visible countries
EU/EEA rate: 6.2 per 100 000
adjusted for reporting delay
New HIV diagnoses, 2017, EU/EEA
Rate per 100 000 population
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
5. 5
Non-visible countries
EU/EEA rate: 9.0 per 100 000
New HIV diagnoses in men,
2017, EU/EEA
Rate per 100 000 male population
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
6. 6
Non-visible countries
EU/EEA rate: 2.8 per 100 000
New HIV diagnoses in women,
2017, EU/EEA
Rate per 100 000 female population
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
7. 7
Non-visible countries
New HIV diagnoses attributed to
sex between men, 2017, EU/EEA
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
Rate per 100 000 male population
8. 8
Non-visible countries
New HIV diagnoses attributed to
heterosexual transmission, 2017,
EU/EEA
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
Rate per 100 000 population
9. 9
New HIV diagnoses attributed to
injecting drug use, 2017, EU/EEA
Non-visible countries
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
Rate per 100 000 population
10. 10
Non-visible countries
AIDS diagnoses, 2017, EU/EEA
EU/EEA rate: 0.7 per 100 000
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
Rate per 100 000 population
11. 11Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
EU/EEA male-to-female ratio: 3.1
Male-to-female ratio in new HIV
diagnoses, by country, EU/EEA, 2017
12. Age- and gender-specific rates of HIV
diagnoses per 100 000 population,
EU/EEA, 2017
12
Men
Women
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
13. 13
<15 years
15-19 years
20-24 years
25-29 years
30-39 years
40-49 years
50+ years
Percentage of new HIV diagnoses, by
country and age group, EU/EEA, 2017
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
Note: Germany did not report data for 2017, 0 cases were reported by Liechtenstein
14. 14
New HIV diagnoses, by transmission
mode and age group, EU/EEA, 2017
15-19 years 20-24 years 25-29 years 30-39 years 40-49 years 50+ years
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
15. 15
Proportion of new HIV diagnoses, by
country and transmission, EU/EEA, 2017
Injecting
drug use
Heterosexual
contact (males)
Sex between men
Other/
undetermined
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
Heterosexual
contact (females)
Note: Germany did not report data for 2017, 0 cases were reported by Liechtenstein
16. 16
Proportion HIV diagnoses in migrants*
by country of report and region of
origin, EU/EEA 2017
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
EU/EEA: 41% diagnosed in
2017 were born abroad
Central and Eastern Europe
* Migrants include all persons born outside of
the country in which the diagnosis was made.
Sub-Saharan Africa
Western Europe
Latin American and Caribbean
South and Southeast Asia
Other
Data include only cases with known region of origin;
No data were reported by Germany in 2017 and zero cases were reported
among migrants in Hungary or Liechtenstein
17. 17
Proportion of persons diagnosed late*
with HIV by demographic, EU/EEA,
2017
Age group (years) Transmission Region of originGender
*Diagnosed late=CD4<350 cells/mm3 at diagnosis
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
18. 18
Proportion of HIV cases diagnosed
late, 2017, EU/EEA
% persons with CD4
<350 cells/mm3 at HIV diagnosis
EU/EEA average: 49%
Non-visible countries
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
19. 19
New reported HIV diagnosis and
estimated infections, EU/EEA, 2008-
2017
Source: Estimates from UNAIDS, 2018; ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
20. 20
HIV diagnoses, AIDS diagnoses
and AIDS-related deaths per 100 000
population, EU-EEA, 2008-2017
Note: HIV rate is adjusted for reporting delay. Deaths rate exclude countries not reporting deaths consistently over the period (Belgium,
Germany, Italy, Sweden)
HIV
AIDS
AIDS-
related
deaths
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
21. 21
15-19 years
20-24 years
25-29 years
30-39 years
40-49 years
50+ years
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
New HIV diagnoses, by age group,
EU-EEA, 2008-2017
22. 22
New HIV diagnoses in men, by age
group, EU-EEA, 2008-2017
15-19 years
20-24 years
25-29 years
30-39 years
40-49 years
50+ years
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
23. 23
New HIV diagnoses in women, by age
group, EU-EEA, 2008-2017
15-19 years
20-24 years
25-29 years
30-39 years
40-49 years
50+ years
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
24. 24
HIV diagnoses, by route of
transmission, 2008-2017, EU/EEA
Injecting drug use
Heterosexual
(women)
Heterosexual
(men)
Sex between men
Other/
undetermined
Vertical
transmission
Data are adjusted for reporting delay. HIV diagnoses reported by Estonia and Poland excluded due to incomplete reporting on transmission mode during
some years of the period; diagnoses reported by Germany, Italy and Spain excluded due to incomplete reporting during a portion of the period.
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
25. 25
Proportion of HIV diagnoses,
by route of transmission,
2008-2017, EU/EEA
Injecting
drug use
Heterosexual
(women)
Heterosexual
(men)
Sex between
men
Other/
unknown
Vertical
transmission
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
Data are adjusted for reporting delay. HIV diagnoses reported by Estonia and Poland excluded due to incomplete reporting on transmission mode during
some years of the period; diagnoses reported by Germany, Italy and Spain excluded due to incomplete reporting during a portion of the period.
26. 26
New HIV diagnoses, by year of
diagnosis, transmission route and
migration status, EU/EEA, 2008-2017
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
Data are adjusted for reporting delay. HIV diagnoses reported by Estonia and Poland excluded due to incomplete reporting on transmission mode during
some years of the period; diagnoses reported by Germany, Italy and Spain excluded due to incomplete reporting during a portion of the period.
27. 27
Proportion of HIV diagnoses in
migrants, by region of origin,
2008-2017, EU/EEA
* Migrants include all persons born outside of the reporting country
Central and Eastern
Europe
Sub-Saharan Africa
Western Europe
Latin American and
Caribbean
South and Southeast Asia
Other
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
Data are adjusted for reporting delay. HIV diagnoses reported by Estonia and Poland excluded due to incomplete reporting on transmission mode during
some years of the period; diagnoses reported by Germany, Italy and Spain excluded due to incomplete reporting during a portion of the period.
28. 28
Median CD4 cell count per mm3 at HIV
diagnosis, overall and by route of HIV
transmission, EU/EEA, 2008-2017
Note: Excludes countries with >60% incomplete data on CD4 cell count during any year over the period (Bulgaria, Croatia, Estonia, Germany, Hungary, Italy, Ireland,
Latvia, Lithuania, Malta, Norway, Poland, Portugal, Sweden). Acute infections are excluded from this analysis.
Injecting drug use
Sex between men
All new diagnoses
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
Heterosexual
(women)
Heterosexual
(men)
29. Time to linkage to care after HIV
diagnosis, by route of transmission,
EU/EEA, 2017
29Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
Note: Data presented here exclude individuals who did not have a CD4 count reported after diagnosis
30. 30
AIDS > 90 days after HIV
diagnosis
Proportion of AIDS diagnoses within
90 days of HIV diagnosis, by route of
HIV transmission, EU/EEA, 2017
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
AIDS < 90 days of HIV
diagnosis
31. 31
Other/
unknown
AIDS diagnoses, by route of HIV
transmission, EU/EEA, 2008-2017
Source: ECDC/WHO (2018). HIV/AIDS Surveillance in Europe 2018– 2017 data
Injecting drug
use
Sex between men
Heterosexual
(women)
Heterosexual
(Men)
Note: Data from Germany, Belgium and Sweden excluded due to inconsistent reporting during the period
32. 32
Proportion of persons diagnosed
with AIDS with tuberculosis as an
AIDS-defining illness, EU/EEA, 2017
Countries that did not report AIDS (Belgium, Germany and Sweden) or reported no cases of TB as
an AIDS-defining illness (Croatia, Cyprus, Estonia, Greece, Hungary, Iceland, Ireland, Luxembourg,
Norway, Slovakia, and Slovenia) are excluded
EU/EEA average: 14%
Source: ECDC/WHO (2018). HIV/AIDS
Surveillance in Europe 2018– 2017 data
33. 33
Conclusions: EU/EEA (1)
Although preventable through effective public health measures,
significant HIV transmission continues in the EU/EEA
Key findings on HIV in EU/EEA countries
• Sex between men accounted for the largest proportion of cases
diagnosed (38%),
• 41% of new HIV diagnoses were among people originating from
outside of the reporting country,
• There is evidence of a decline in the rate of new HIV diagnoses in the
EU/EEA as a whole.
• Despite the overall decline, HIV rates continue to increase in one-third
of EU/EEA countries.
• Nearly half (49%) of people were diagnosed late, with a CD4 cell count
of <350/mm3 at diagnosis.
Source: ECDC/WHO (2016). HIV/AIDS Surveillance in Europe, 2015
34. Conclusions: EU/EEA (2)
Evidence-based HIV prevention interventions tailored to the local
epidemiological context and targeted at those most at risk should be
sustained and scaled up.
• Expansion of HIV testing and linkage to care will ensure early
diagnosis and access to treatment; this will reduce the number of
late presenters and improve treatment outcomes.
• Programmes for men who have sex with men should be a
cornerstone of HIV prevention in all EU/EEA countries
• Given the high proportion of HIV cases among migrants in many
EU/EEA countries, and evidence of post-migration HIV acquisition,
migrant-sensitive prevention services are crucial
• Adequate harm reduction levels will continue to prevent HIV
among people who inject drugs
34Source: ECDC/WHO (2016). HIV/AIDS Surveillance in Europe, 2015
35. 35
Full report is
available at
www.ecdc.europa.eu
and
http://bit.ly/HIVsur_18
Questions
STIHIVHEP@ecdc.europa.eu